Home > Journals > Minerva Pediatrics > Past Issues > Minerva Pediatrica 2020 October;72(5) > Minerva Pediatrica 2020 October;72(5):358-63

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW  NOVEL INSIGHTS INTO PEDIATRIC ALLERGY AND IMMUNOLOGY Freefree

Minerva Pediatrica 2020 October;72(5):358-63

DOI: 10.23736/S0026-4946.20.05967-8

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Pidotimod in allergic diseases

Sara MANTI , Giuseppe F. PARISI, Maria PAPALE, Salvatore LEONARDI

Unit of Pediatric Respiratory, Department of Clinical and Experimental Medicine, AOU Vittorio Emanuele Polyclinic, San Marco Hospital, University of Catania, Catania, Italy



The rising incidence of allergic disease requires more specific, effective and safe therapeutic strategies. In this regard, several kinds of biologically active substances, commonly known as immunostimulants, have been introduced for the prevention and treatment of allergic diseases in pediatric population. Among the heterogeneous group of biologically active molecules to date available, pidotimod (Axil, Valeas S.p.A, Milan) is proved to be able to ameliorate both innate and adaptive immunity and enhances the immune system properties often impaired in patients with allergic disorders.


KEY WORDS: Asthma; Dermatitis, atopic; Child; Chronic urticaria; Pidotimod; Rhinitis

top of page